Skip to main content
DOUBLE MEDICAL TECHNOLOGY INC. logo

DOUBLE MEDICAL TECHNOLOGY INC. — Investor Relations & Filings

Ticker · 002901 ISIN · CNE1000032W7 LEI · 836800DECKX5CGFNMD42 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 963 across all filing types
Latest filing 2024-10-30 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002901

About DOUBLE MEDICAL TECHNOLOGY INC.

https://www.double-medical.com

Double Medical Technology Inc. specializes in the development, manufacturing, and distribution of medical devices, with a primary focus on orthopedic solutions. The company's extensive product portfolio includes trauma fixation systems, spinal implants, joint prosthesis, and neurosurgical devices. Additionally, it provides specialized surgical instruments and advanced wound care products. Double Medical emphasizes research and innovation to deliver clinically effective solutions for complex musculoskeletal conditions. Its manufacturing processes adhere to international quality standards, ensuring the reliability of its implants and instruments used in hospitals and surgical centers worldwide. The company serves a global market, providing comprehensive support for orthopedic surgeons through its diverse range of reconstructive and regenerative medical technologies.

Recent filings

Filing Released Lang Actions
关于向2024年股票期权激励计划激励对象首次授予股票期权的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the initial grant of stock options under its 2024 stock option incentive plan. It details the number of options granted, the exercise price, the eligibility criteria, approval procedures, and legal opinions. The content focuses on the granting of stock options to employees and management, which is a capital/financing activity related to equity incentives. It is not a full financial report, earnings release, or management discussion, but rather a specific update on a financing-related event involving stock options. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a mere announcement of a report but a substantive disclosure of a financing event.
2024-10-30 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from 大博医疗科技股份有限公司 dated October 31, 2024. It reports the decisions made at the third board's 14th meeting, including approval of the 2024 third quarter report, stock option incentive plan, and share repurchase plan. The document references other detailed reports and announcements published separately on October 31, 2024, on the company's designated disclosure media and the cninfo website. The text itself does not contain the full financial report or detailed financial data but rather summarizes the board's resolutions and points readers to the full reports elsewhere. The document is short (1685 characters) and serves as an official announcement of board meeting resolutions and related approvals, including the approval of the quarterly report and share repurchase plan. This fits best under Board/Management Information (MANG) as it announces board decisions and management actions rather than providing the full quarterly report or financial statements. It is not a full Interim/Quarterly Report (IR) because it lacks substantive financial data and analysis, and it is not a Regulatory Filing (RNS) because it is a formal board resolution announcement. Therefore, the classification is MANG with high confidence.
2024-10-30 Chinese
2024年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "大博医疗科技股份有限公司2024年第三季度报告" which translates to "Dabo Medical Technology Co., Ltd. 2024 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the third quarter of 2024. The document includes audited financial figures, mentions of non-recurring gains and losses, shareholder information, and other comprehensive financial disclosures typical of a quarterly financial report. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is a full interim/quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2024
2024-10-30 Chinese
2024年股票期权激励计划首次授予激励对象名单（授权日）
Share Issue/Capital Change Classification · 95% confidence The document is titled as a list of recipients for the company's 2024 stock option incentive plan initial grant, including detailed names, positions, and stock option allocations. It is issued by the company's board of directors and dated October 31, 2024. The content focuses on the allocation of stock options to core management and technical personnel, which is a capital-related announcement concerning equity incentives. There is no financial statement or quarterly/annual report data, nor is it a meeting presentation or voting result. It is not a report publication announcement but a direct disclosure of stock option grants. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA), as it relates to stock option grants and equity incentives.
2024-10-30 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the 13th meeting of the 3rd Supervisory Board of Dabao Medical Technology Co., Ltd. It includes approval of the 2024 Q3 report and the initial grant of stock options under the 2024 stock option incentive plan. The document states that the Supervisory Board reviewed and approved the 2024 third quarter report but does not contain the report itself; it refers readers to the full report published on October 31, 2024, on the company's designated disclosure media and the CNINFO website. The document is short (1169 characters) and serves as an official announcement of meeting resolutions and approvals rather than the full quarterly report or detailed financial data. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-10-30 Chinese
关于回购公司股份方案实施完成暨股份变动的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from a company about the completion of its share repurchase (buyback) program and the resulting changes in shareholding. It details the number of shares repurchased, prices, compliance with regulations, and the intended use of the repurchased shares for an equity incentive plan. The document references previous announcements and regulatory compliance but does not contain financial statements or detailed financial analysis. It is a formal disclosure about the company's transaction in its own shares, specifically a share buyback completion and shareholding changes. Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length is under 5,000 characters, but it is a full announcement of the transaction completion, not just a notice of report publication or a certification. Hence, the correct classification is POS with high confidence.
2024-10-30 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.